Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Dr David Stamler’s Biotech Showcase Presentation

January 7, 2019 Kerry Rowe

Prana Biotechnology BSC Presntation 20180107 FINAL

Post navigation

Prana Presents at Biotech Showcase

Prana receives Orphan Designation for PBT434 for treatment of MSA

Related Posts

Prana provides regulatory update for PBT2 for the treatment of Huntington disease

November 2, 2016

Annual General Meeting Presentation 2017

November 17, 2017

Prana Doses First Patient in the “IMAGINE” Phase II Alzheimer’s Disease Trial

July 17, 2013

Recent Posts

Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study
Alterity completes Placement Tranche 1 raising $10M
Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.
XBRL 30 June 2020 filed with the SEC
New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065